Stereotactic body radiotherapy (SBRT) of adrenal metastases
Sponsor-Investigator:
PD Dr. Judit Boda-Heggemann /PD Dr. Daniel Buergy
Universitätsmedizin Mannheim
daniel.buergy@medma.uni-heidelberg.de
Study objective:
To analyze the toxicity and efficacy of targeted radiotherapy to adrenal metastases
Project status
- Data collection completed
- Two full articles published
Major findings and results
Buergy D, Würschmidt F, Gkika E, et al. Stereotactic body radiotherapy of adrenal metastases-A dose-finding study. Int J Cancer. 2022; 151(3):412-421. https://pubmed.ncbi.nlm.nih.gov/35383919/
- Dose-volume parameters available in 218 patients treated with SBRT
- Biologically effective dose (BED10) cut-point analyses indicated optimal dose cut-points as follows:
- PTV-D50%: 73.2 Gy
- PTV-D2%: 78.0 Gy
- GTV-D50%: 74.2 Gy
- GTV-mean: 73.0 Gy
- If these dose levels were achieved, local recurrence rates (LRR) were significantly reduced compared to patients who received lower doses.
- Further dose escalation was not associated with improved LRR in our patient cohort (e.g., PTV-D50% values of 73.2-85.9 Gy compared to doses above 85.9 Gy)
Buergy D, Würschmidt F, Gkika E, et al. Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis. Int J Cancer. 2021; 149(2):358-370. https://pubmed.ncbi.nlm.nih.gov/33682927/
- 366 lesions included in the analysis (260 treated with SBRT)
- Toxicity mostly mild; however, four cases of adrenal insufficiency occurred, 2 of which were likely caused by immunotherapy or tumor progression
- Freedom from local progression after one year was associated with improved overall survival
Project status:
- Study closed (219 patients recruited)
- Follow-up ongoing